Humalog /ml Kwikpen

Insulin lispro is a rapid-acting human insulin analogue produced via recombinant DNA technology in Escherichia coli, employed for glycemic control in individuals with type 1 and type 2 diabetes mellitus.[1][2] Chemically, it consists of the same empirical formula (C257H383N65O77S6) and molecular weight (5808 daltons) as endogenous human insulin but features an inversion of the proline-lysine residues at B-chain positions 28 and 29, which diminishes hexamer formation and promotes swift dissociation into monomers upon injection.[3][4] This structural modification yields an onset of action within 10 to 15 minutes, a peak effect at 30 to 90 minutes, and a duration of 3 to 5 hours, enabling administration immediately before or within 15 minutes after meals for effective postprandial glucose management.[4][5]